Moderna Wavers Despite FDA Win; Will Its Sprint Restart?

Moderna Wavers Despite Hard-Fought FDA Win; Will Its Sprint Restart?

Licensing

10:13 AM ET 08/06/2026

Moderna (MRNA) stock wavered Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva. The approval comes after a lengthy battle with former FDA authorities. Previously, the FDA refused to review Moderna's application, saying the study wasn't "adequate or well controlled" and the standard flu shot it used in comparison didn't reflect the best available…

Moderna Wavers Despite FDA Win; Will Its Sprint Restart?

Other newsrooms on this story

Related reading

Moderna's mRNA flu shot mFlusiva snags FDA nod after refusal-to-file imbroglio

US regulators approve Moderna flu vaccine

FDA Panel Set To Debate Moderna Flu Shot - Moderna (NASDAQ:MRNA)

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

Moderna's mRNA flu shot earns FDA approval after rollercoaster review

FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal